Pfizer tops Q1 forecasts; vaccine sales slide as expected

[ASFN Admin]

Pfizer topped Wall Street expectations Tuesday even as sales of its top-selling COVID-19 vaccine crumbled in the first quarter. Revenue from Pfizer’s Comirnaty vaccine fell 77% to $3 billion in the first three months of the year, compared with more than $13 billion in the same stretch last year. The drop was widely expected because the drugmaker is moving this year from supplying governments through big contracts to selling the vaccine on the commercial market.

Continue reading...